Consultation Submission: OTC Nasal Decongestant Preparations For

Total Page:16

File Type:pdf, Size:1020Kb

Consultation Submission: OTC Nasal Decongestant Preparations For 05 May 2014 RASML Officer OTC Medicines Evaluation Office of Medicines Authorisation Therapeutic Goods Administration PO Box 100 WODEN ACT 2606 Dear Sir/Madam, Re: OTC nasal decongestant preparations for topical use - proposed advisory statements for labelling Novartis Consumer Health (NCH) is the manufacturer and distributor of Otrivin® containing xylometazoline hydrochloride as the active ingredient. We appreciate the opportunity to respond to the consultation on the proposed advisory statements for OTC nasal decongestant preparations for topical use. Our comments on the proposed Required Advisory Statements for Medicine Labels (RASML) are discussed below. 1. Proposed advisory statement: "Frequent or prolonged use may cause nasal congestion to recur or worsen." NCH supports this advisory statement, as it provides clear information for consumers on why the medicine should not be used more frequently or longer than directed. 2. Proposed advisory statement: "Do not use for more than three days at a time unless advised by a doctor or pharmacist." NCH proposes to amend this statement to "Do not use for more than three five days at a time unless advised by a doctor or pharmacist." We agree that consumers need clear instructions on the maximum duration of use. However, the recommendation for 3 days is inconsistent with the body of clinical evidence and Australian standard reference texts. Clinical evidence Topical nasal decongestants are widely used to alleviate symptoms of rhinitis. These products are very effective at rapidly improving nasal congestion1, a symptom which may in turn cause insomnia, snoring and disturbed sleep1,2. Current evidence suggests prolonged or repeated use of topical decongestants can cause problems, leading to the development of rhinitis medicamentosa (RM), commonly known as rebound congestion. This phenomenon becomes more frequent the longer the decongestant is used1,3,4,5,6. It’s understandable that when this occurs, patients become uncertain as to whether congestion is still being caused by the nasal disease or by RM. For this reason NCH agrees that there should be a statement on the packaging giving consumers clear instructions on the maximum duration of use. However, the timeframe of 3 days is inconsistent with the body of clinical evidence, and the mean duration of nasal symptoms experienced throughout the common cold; four to five days7,8,9. The rebound effect of topical decongestants has only been described experimentally in healthy subjects10,11,12,13. Despite the fact that there are a similar number of studies in healthy subjects that failed to demonstrate any rebound effect14,15,16,17, the results from these studies cannot be directly extrapolated to patients with rhinosinusitis. The nasal mucosa of healthy subjects is not subjected to the cytokine environment associated with inflammation. The inflamed nasal mucosa treated with a topical decongestant does not present the same absorption properties as healthy nasal mucosa1. Evaluation of the congestion possibly induced by a topical nasal decongestant is consequently biased. Randomised controlled trials conducted in subjects with inflammation of the nasal mucosa, show no signs of RM after treatment times of up to ten days. This is shown for studies conducted with xylometazoline18,19,20,21 and oxymetazoline22,23. Subsequently, the majority of clinical reviews recommend limiting treatment time to ten days2,3,6,11,24, with some cautiously recommending up to 7 days5,25,26,27. Only one review had their lower limit of recommendation as 3 days5. The justification was not based on evidence but on the assumption that if a consumer was to choose to use it for longer, they still will be within a safe limit of use. However, supporting this rationale could encourage consumers to take a relaxed approach to medication labelling once they become aware directions for use can be extended. Australian standard reference texts Australian healthcare professionals frequently refer to the Therapeutic Guidelines, Australian Medicines Handbook (AMH), PSA's Non-prescription Medicines in the Pharmacy and Australian Pharmaceutical Formulary and Handbook (APF). In particular, the AMH and APF are standard texts required to be kept in pharmacies as per the Pharmacy Board practice standards and these are the references used by the majority of practicing pharmacists. NCH notes that all the above references recommend a treatment duration of no more than 5 days, due to the risk of rebound congestion: Australian Therapeutic Guidelines28: “maximum of 5 days” for oxymetazoline, tramazoline and xylometazoline. AMH29: “Do not use this medicine more than recommended or for more than 5 days at a time as it can worsen your symptoms when you stop using it.” PSA’s Non-Prescription Medicines in the Pharmacy30: “Nasal decongestants should not be used for longer than 5 days at a time.” APF31: “Topical decongestants should not be used for more than 5 days: prolonged use causes rebound congestion.” NCH believes that the proposed advisory statements should be aligned with the standard reference texts used by Australian healthcare professionals. References 1. Mortuaire G, de Gabory L, François M, Massé G, Bloch F, Brion N, Jankowski R, Serrano E. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013 Jun;130(3):137-44. 2. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med. 2005;4(1):21- 9. 3. Graf P. Rhinitis medicamentosa. Clin Allergy Immunol. 2007;19:295-304. 4. Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16(3):148-55. 5. Rudy SF. Preventing and treating rhinitis medicamentosa. Nurse Pract. 1997 Nov;22(11):13, 115-6. 6. Passàli D, Salerni L, Passàli GC, Passàli FM, Bellussi L. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf. 2006 Nov;5(6):783-90. 7. Turner R. Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 1997;78:531– 40. 8. Heikkinen T, Järvinen A. The common cold. Lancet 2003; 361: 51–59. 9. De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant- analgesic combinations for the common cold. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD004976. 10. Morris S, Eccles R, Martez SJ, et al. An evaluation of nasal response following different treatment regimes of oxymetazoline with references to rebound congestion. Am J Rhinol 1997;11:109—15. 11. Akerlund A, Bende M. Sustained use of xylometazoline nose drops aggravates vasomotor rhinitis. Am J Rhinol 1991;5:157—60. 12. Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology 1996;34:9—13. 13. Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010;182:19—24. 14. Yoo JK, Seikaly H, Calhoun KH. Extended use of topical nasal decongestants. Laryngoscope 1997;107:40—3. 15. Watanabe H, Foo TH, Djazeri B. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology 2003;41:167—74. 16. Petruson B, Hansson HA. Function and structure of the nasal mucosa after 6 weeks use of nose drops. Acta Otolaryngol (Stockh) 1982;94:563—9 17. Petruson B. Treatment with xylometazoline (Otrivin) nosedrops over a six-week period. Rhinology. 1981; 19:167-72. 18. Eccles, R., Eriksson, M., Garreffa, S., and Chen, S.C., The nasal decongestant effect of xylometazoline in the common cold, Am J Rhinol 22, 1–22, 2008 19. Eccles, R., Pedersen, A., Regberg, D., Tulento, H., Borum, P., Stjärne, P. Efficacy and safety of topical combinations of ipratropium and xylometazoline for the treatment of symptoms of runny nose and nasal congestion associated with acute upper respiratory tract infection. Am J Rhinol. 2007 Jan-Feb;21(1):40-5 20. Graf, P., Juto, J.-E., Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling. Rhinology, 33, 14-17, 1995 21. Strandell, B., Norgren-Holst, E., Tran, N., Jakobsen, H.B., and Chen, S. OTC use of a topical nasal spray solution containing xylometazoline plus ipratropium in patients with common cold. International Journal of Clinical Pharmacology and Therapeutics, Vol. 47 – No. 12/2009 (744-751) 22. Graf, P., Enerdal, J., Hallén, H. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis. Arch Otolaryngol Head Neck Surg. 1999 Oct;125 (10):1128-32. 23. Morris, S., Eccles, R., Martez, S.J., Riker, D.K., Witek, T.J. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Am J Rhinol. 1997 Mar-Apr;11 (2):109-15. 24. Graf, P.and Juto J. Correlation between objective nasal mucosal swelling and estimated stuffiness during long-term use of vasoconstrictors. ORL 1994;56:334-339 25. Archontaki M1, Symvoulakis EK, Hajiioannou JK, Stamou AK, Kastrinakis S, Bizaki AJ, Kyrmizakis DE. Increased frequency of rhinitis medicamentosa due to media advertising for nasal topical decongestants. B-ENT. 2009;5(3):159-62. 26. Black MJ, Remsen KA. Rhinitis medicamentosa. Can Med Assoc J. 1980 Apr 19;122(8):881-4. 27. Stübner UP1, Toth J, Marks B, Berger UE, Burtin B, Horak F. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittelforschung. 2001 Nov;51(11):904-10. 28. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2013 Mar. Accessed 2013 April 15 http://online.tg.org.au/complete/desktop/index.htm. 29. Australian Medicines Handbook 2014 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2014 January.
Recommended publications
  • Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers with Topical Pharmaceutical Agents
    Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents Author Watts, Annabelle M, Cripps, Allan W, West, Nicholas P, Cox, Amanda J Published 2019 Journal Title FRONTIERS IN PHARMACOLOGY Version Version of Record (VoR) DOI https://doi.org/10.3389/fphar.2019.00294 Copyright Statement © Frontiers in Pharmacology 2019. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version. Downloaded from http://hdl.handle.net/10072/386246 Griffith Research Online https://research-repository.griffith.edu.au fphar-10-00294 March 27, 2019 Time: 17:52 # 1 REVIEW published: 29 March 2019 doi: 10.3389/fphar.2019.00294 Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents Annabelle M. Watts1*, Allan W. Cripps2, Nicholas P. West1 and Amanda J. Cox1 1 Menzies Health Institute Queensland, School of Medical Science, Griffith University, Southport, QLD, Australia, 2 Menzies Health Institute Queensland, School of Medicine, Griffith University, Southport, QLD, Australia Allergic rhinitis (AR) is a chronic upper respiratory disease estimated to affect between 10 and 40% of the worldwide population. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators, and cytokines. As such, the development of a single drug to treat allergic inflammation and/or symptoms is confounded by the complexity of the disease pathophysiology. Complete avoidance of allergens that trigger AR symptoms is not possible and without a cure, the available therapeutic options are typically focused on achieving symptomatic relief.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Epinephrine Versus Tramazoline to Reduce Nasal Bleeding During Nasotracheal Intubation. a Double- Blind Randomized Trial
    Epinephrine versus tramazoline to reduce nasal bleeding during nasotracheal intubation. A double- blind randomized trial Aiji Sato(Boku) ( [email protected] ) Aichi Gakuin University Yoshiki Sento Nagoya City University Yuji Kamimura Nagoya City University Eisuke Kako Nagoya City University Masahiro Okuda Aichi Gakuin University Naoko Tachi Aichi Gakuin University Yoko Okumura Aichi Gakuin University Mayumi Hashimoto Aichi Gakuin University Hiroshi Hoshijima Tohoku University Fumihito Suzuki Akita National Hospital Kazuya Sobue Nagoya City University Research Article Keywords: Nasotracheal intubation, Epinephrine, Tramazoline, Nasal bleeding Posted Date: February 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-148779/v1 Page 1/14 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/14 Abstract BACKGROUND Nasal bleeding is the most common complication during nasotracheal intubation (NTI). To reduce nasal bleeding, the nasal cavity is treated with vasoconstrictors (epinephrine [E] or tramazoline [T]) prior to NTI. This study aimed to determine whether E or T is more effective and safe for reducing nasal bleeding during NTI. METHODS This study was preregistered on UMIN-CTR after being approved by the IRB of the School of Dentistry at Aichi Gakuin University. Written consent was received from all the patients. Total 206 patients aged 20–70 years and classied as 1–2 on American Society of Anesthesiologists-physical status were scheduled to undergo general anesthesia with NTI. Patients with a narrowed nasal cavity observed during preoperative CT test (n = 3), patients with hypertension (n = 3), patients undergoing antithrombotic therapy, and patients who did not give consent (n = 3) were excluded from the study.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Rhinitis - Allergic (1 of 15)
    Rhinitis - Allergic (1 of 15) 1 Patient presents w/ signs & symptoms of rhinitis 2 • Consider other classifi cations of rhinitis DIAGNOSIS No - Please see Rhinitis Is allergic rhinitis - Nonallergic disease confi rmed? management chart Yes 3 ASSESS DURATION & SEVERITY OF ALLERGIC RHINITIS A Non-pharmacological therapy • Allergen avoidance • Patient education VAS <5 VAS ≥5 B Pharmacological therapy B Pharmacological therapy • Antihistamines (oral/nasal), &/or • Corticosteroids (nasal), w/ or without • Corticosteroids (nasal), or • Antihistamines (nasal), or • Cromone (nasal), or • LTRA • Leukotriene receptor antagonists (LTRA)MIMS TREATMENT © See next page Specifi cally for patients w/ asthma Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B167 © MIMS Pediatrics 2020 Rhinitis - Allergic (2 of 15) Previously treated symptomatic Previously treated symptomatic patient (VAS <5) on antihistamines patient (VAS ≥5) on intensifi ed (oral/nasal) &/or corticosteroids (nasal) therapy w/ corticosteroids (nasal) w/ or without antihistamines (nasal) Intermittent Persistent symptoms, symptoms or without allergen w/ allergen exposure exposure B Pharmacological therapy B Pharmacological therapy • Step down or discontinue therapy • Continue or step up therapy Untreated REASSESS DISEASE SEVERITY VAS symptomatic patient DAILY UP TO DAY 3 (VAS <5 or ≥5) 4 CONTINUE Yes THERAPY & STEP EVALUATION VAS <5 DOWN THERAPY1 Improvement of symptoms? No VAS ≥5 B Pharmacological therapy • Step-up therapy REASSESS DISEASE SEVERITY MIMSVAS DAILY UP TO DAY 7 4 Yes EVALUATION VAS <5 Improvement of symptoms? No TREATMENT © VAS ≥5 See next page Continue therapy if symptomatic; consider step-down or discontinuation of therapy if symptoms subside Not all products are available or approved for above use in all countries.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • 7-Nose II.Docx ( Updated F1 )
    1 [Color index: Important | Notes | Extra] Editing ​ ​ ​ ​ ​ ​ ​ ​ 2 Diseases of the nose Supernumerary nostril Midline nasal sinus: Nasal clefts: Proboscis lateralis: Incomplete fusion of the right Failure of frontal nasal Due to imperfect fusion and left medial nasal process to develop between the maxillary process prominence. appropriately results into and the lateral nasal process. two separated halves of the nose. Polyrrhinia: Arrhinia: due to bilateral Half nose: due to unilateral absence of nasal placode ​ ​ Duplication of the medial nasal absence of nasal placodes. processes. This is serious because the newborn is a nose breather. mouth breathing is a learning process. Atresia of posterior nares ❖ Types: ● Bony (most commonly) ● Membranous ● Mixed ● Complete unilateral (most commonly) ● Complete bilateral surgical emergency ​ ● Incomplete unilateral ● Incomplete bilateral ❖ Diagnosis: ● Total absence of nasal air flow ● Plastic catheter cannot be passed through the nose ● Post-rhinoscopy ● Radiographs 3 ● Emergency ● Transnasal perforation ● Trans-palatal excision ❖ Management: ﻧﻔﺘﺢ ﻓﻤﻪ ﻓﯿﻀﻄﺮ ﯾﺘﻨﻔﺲ ﻣﻦ ﻓﻤﻪ (Put something to open the mouth (oral airway ● ● Perforate it If membranous ● Surgery (endoscopic) ● In bilateral it is an emergency, in unilateral it is not an emergency and we can wait until the child gains weight then we do surgery. ● Rhinitis refers to inflammatory changes in the nasal mucosa. As the nasal mucosa is continuous ​ ​ ​ ​ ​ ​ over the nose and sinuses, there is nearly always some inflammatory change in the sinuses as 1 well. Hence Rhinosinusitis is​ a better term. ● Types: - acute rhinitis (less than 4 weeks) - chronic rhinitis (more than four consecutive weeks) ● Types based on etiology: 1) Infectious rhinitis(viral/bacterial) 2)Non-allergic Rhinitis,Non-infectious rhinitis -Eosinophilic syndromes(Nares/Nasal polyposis) -NonEosinophilic syndromes(Vasomotor rhinitis/Rhinitis medicamentosa/occupational rhinitis/Rhinitis of pregnancy/hypothyroidism/Medication(OCP).
    [Show full text]
  • Rhinitis (415) 833-3780
    Department of Allergy, Asthma & Immunology Kaiser Permanente San Francisco 1635 Divisadero Street, Suite 101 San Francisco, California 94115 RHINITIS (415) 833-3780 RHINITIS Nasal congestion, runny nose, sneezing, itching, post nasal drip, and sometimes headache are signs of a sensitive and inflamed nose or rhinitis. Rhinitis affects more than 40 million people in the United States. Rhinitis can be allergic or non-allergic. Allergy testing will help differentiate between allergic and non-allergic rhinitis. In addition, allergic rhinitis and non-allergic rhinitis can be present in the same person. ALLERGIC RHINITIS Allergic rhinitis is caused by allergens such as pollens, dust mite, animal dander or mold. Seasonal allergies caused by airborne pollens occur during spring, summer and fall. In contrast, allergies that can occur at any time of the year are caused by indoor allergens such as house dust mite, animals and mold. Eye symptoms, such as itching, tearing, red eye as well as asthma may be present with allergic rhinitis. Testing can be helpful in identifying both seasonal and non-seasonal allergens. For further help on controlling your allergies, please refer to the brochure, Controlling Your Airborne Allergies. Management of Allergic Rhinitis 1. Avoid allergens when possible. 2. Medical Management. The first line of medical therapy is nasal inhaled steroids. Oral medications like antihistamines and decongestants and can be helpful. If you want to use decongestants, you need to discuss their use with your provider. Other medications may be considered by your provider as well. 3. Allergy immunotherapy (shots) may be an option for some patients. NON-ALLERGIC RHINITIS If it isn’t an allergy, what is it? If it isn’t an allergy, most likely it is a condition that mimics allergic rhinitis, known as vasomotor rhinitis.
    [Show full text]
  • 2013 Report on Prohibited Substances
    2013 REPORT ON PROHIBITED SUBSTANCES Compiled by the Racing Medication and Testing Consortium, Supervised by the Advisory Council on Equine Prohibited Substances and Practices of the IFHA Racing Medication and Testing Consortium 821 Corporate Drive, Lexington, KY 40503, USA Phone +1(859) 224-2844 Fax +1(859) 296-3033 rmtcnet.com I. RACING DAY SAMPLES TOTAL DECLARED TOTAL DECLARED BOTH BOTH DECLARED DECLARE DECLARED DECLARE POSITIVE TOTAL TOTAL TOTAL URINE URINE BLOOD BLOOD NUMBER TOTAL DECLARED TOTAL POSITIVE HORSES HORSES URINE & URINE & TOTAL TOTAL DECLARED POSITIVE D POSITIVE D CASES ON SUBSTANCES NUMBER NUMBER BOTH ONLY ONLY ONLY ONLY OF DECLARED DECLARED POSITIVE DECLARED CASES ON SAMPLED SAMPLED BLOOD BLOOD URINE BLOOD POSITIVES CASES ON POSITIVE CASES ON POSITIVE BOTH DETECTED IN COUNTRY OF RACES OF URINE & SAMPLED SAMPLED SAMPLED SAMPLED DECLARE POSITIVES POSITIVE CASES ON POSITIVE BOTH PRE- POST- SAMPLED SAMPLED ONLY ONLY POST- URINE CASES ON BLOOD CASES ON URINE & OTHER HORSE (flat & HORSES BLOOD PRE- POST- PRE- POST- D PRE-RACE CASES ON URINE PRE- CASES ON URINE & RACE RACE PRE- POST- SAMPLED SAMPLED RACE POST- BLOOD POST- BOTH BLOOD COMPETITIONS jumps) SAMPLED SAMPLED RACE RACE RACE RACE POSITIVE URINE RACE BLOOD BLOOD RACE RACE RACE PRE-RACE RACE URINE & POST- CASES PRE-RACE BLOOD RACE Argentina 5,475 11,432 199 10,930 313 116 116 Australia 19,626 45,384 17,823 27,561 70 52 17 35 18 1 17 Austria 122 34 34 18 18 16 16 0 Bahrain 26 223 223 88 88 135 135 1 1 1 Belgium 189 183 157 26 0 Brazil 5,570 5,570 414 414 4,836 4,836 320
    [Show full text]
  • Intranasal Delivery: an Approach to Bypass the Blood Brain Barrier S
    Educational Forum Intranasal delivery: An approach to bypass the blood brain barrier S. Talegaonkar, P. R. Mishra ABSTRACT The blood brain barrier (BBB) represents one of the strictest barriers of in vivo therapeutic drug delivery. The barrier is defined by restricted exchange of hydrophilic compounds, small proteins and charged molecules between the plasma and central nervous system (CNS). For decades, the BBB has prevented the use of many therapeutic agents for treating Alzheimer’s disease, stroke, brain tumor, head injury, spinal cord injury, depression, anxiety and other CNS disorders. Different attempts were made to deliver the drug across the BBB such as modification of therapeutic agents, Department of altering the barrier integrity, carrier-mediated transport, invasive techniques, etc. However, open- Pharmaceutics, Jamia ing the barrier by such means allows entry of toxins and undesirable molecules to the CNS, result- Hamdard, New Delhi - ing in potentially significant damage. An attempt to overcome the barrier in vivo has focused on 110062, India. bypassing the BBB by using a novel, practical, simple and non-invasive approach i.e. intranasal Received: 7.4.2003 delivery. This method works because of the unique connection which the olfactory and trigeminal Revised: 1.10.2003 nerves (involved in sensing odors and chemicals) provide between the brain and external environ- Accepted: 18.1.2004 ments. The olfactory epithelium acting as a gateway for substances entering the CNS and periph- eral circulation is well known. Also, it is common knowledge that viral infections such as common Correspondence to: cold, smallpox, measles, and chicken pox take place through the nasopharynx.
    [Show full text]
  • Research Article Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis
    Hindawi Publishing Corporation Journal of Allergy Volume 2014, Article ID 292545, 12 pages http://dx.doi.org/10.1155/2014/292545 Research Article Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis Andrea Eichel,1 Andreas Bilstein,2 Nina Werkhäuser,2 and Ralph Mösges1 1 Institute of Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Lindenburger Allee 42, 50931 Cologne, Germany 2 Bitop AG, Stockumer Straße 28, 58453 Witten, Germany Correspondence should be addressed to Andrea Eichel; [email protected] Received 15 January 2014; Revised 14 April 2014; Accepted 15 April 2014; Published 11 May 2014 Academic Editor: Desiderio Passali Copyright © 2014 Andrea Eichel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives. The meta-analysis aims to investigate the efficacy of ectoine nasal spray and eye drops in the treatment of allergic rhinitis and rhinoconjunctivitis symptoms. Design and Methods. This meta-analysis is based on yet unpublished data of four studies. Both nasal and eye symptoms were documented in patient diary cards. All scales were transformed into a 4-point scale: 0 = no, 1 = mild, 2 = moderate, and 3 = severe symptoms. Each symptom was analysed individually in a meta-analysis of the area under the curve values as well as in a meta-analysis of pre- and posttreatment comparison. Results. After seven days of treatment with ectoine nasal spray both nasal and ocular symptoms decreased significantly.
    [Show full text]
  • How Toxic Indeed Is Oxymetazoline? Collection and Comparison of Toxicological Data of Pharmacologically Active Imidazoline Derivatives
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 December 2020 doi:10.20944/preprints202011.0416.v2 Article How Toxic indeed is Oxymetazoline? Collection and Comparison of Toxicological Data of Pharmacologically Active Imidazoline Derivatives Karsten Strey1,* 1 Humboldtstr. 105, D-22083 Hamburg, Germany * Correspondence: [email protected]; Abstract. Imidazoline derivatives, such as xylometazoline, naphazoline, tetryzoline, tramazoline or oxymetazoline play an important pharmacological role as nasal drops in the symptomatic treatment of rhinitis. When comparing the toxicological data of these substances, it is noticeable that Oxymetazoline has an LD50 value which is two orders of magnitude lower than all other imidazoline derivatives. Thus, ten vials of commercially available oxymetazoline nasal drops already contain a lethal amount. An explanation for this unusually high toxicity has not yet been found. Keywords. LD50, lethal Dose, Xylometazoline, Oxymetazoline, Imidazoline Derivatives 1. Introduction Many imidazoline derivatives are basic substances for pharmaceutical products. In 1941, the pharmacological effect of imidazoline derivatives was discussed for the first time on mucous membranes [1]. In 1955, Sahyun Labs secured several synthetic routes for imidazoline derivatives, including the tetryzoline [2]. Xylometazoline was first produced by A. Hüni in 1959 [3]. This was followed by the synthesis of oxymetazoline by W. Fruhstorfer and H. Müller-Calgan in 1961 [4]. Since the decongestant effect of oxymetazoline for the nose lasted longer than with other imidazoline derivatives, an oxymetazoline product was part of the on-board pharmacy of Apollo 11 on its way to the moon in 1969 [5]. Nowadays, the imidazoline derivatives xylometazoline, tramazoline, naphazoline, tetryzoline and oxymetazoline are important drugs for nasal decongestion and as ingredients for eye drops.
    [Show full text]